RSPO2 and neoplasm: Indeed, recurrent activating RSPO2 and RSPO3 gene fusions were found to occur in 10% of human colon tumors [13] and a recent follow-up study targeting RSPO3 in a RSPO3-fusion tumor xenograft model was shown to downregulate genes expressed in the stem cell compartment and inhibit tumor growth [29].